[1] |
尹如铁,李克敏,李玉玲,等.罕见类型的子宫颈癌诊治进展[J].西部医学,2014,26(5):537–540.
|
[2] |
Bansal S,Lewin SN,Burke WM,et al.Sarcoma of the cervix: natural history and outcomes[J]. Gynecol Oncol, 2010,118(2):134–138.
|
[3] |
NCCN Clinical Practice guidelines in Oncology: uterine sarcoma(2014)EB/OL. National Comprehensive Cancer Network,Inc.
URL
|
[4] |
Chin PS,Chia YN,Lim YK.et al.Diagnosis and management of Müllerian adenosarcoma of the uterine cervix[J]. Int J Gynecol Obstet, 2013,121(3):229–232.
|
[5] |
Bernard B, Clarke BA, Malowany JI, et al. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival[J].Gynecol Oncol,2013,131(3): 634–639
|
[6] |
Yulan MU, Ming LIU, Min SHI, et al. Clinical analysis of alveolar soft tissue sarcoma of the uterine cervix: a case report[J]. Chin Med J, 2010,123(12):1612–1614.
|
[7] |
Hasegawa K,Ichikawa R,Ishii R,et al. A case of primary alveolar soft part sarcoma of the uterine cervix and a review of the literature[J].Int J Clin Oncol, 2011, 16(6):751–758.
|
[8] |
Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a cliniopathologic study of 35 cases[J]. Cancer,1981,48(2):354–366.
|
[9] |
Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature[J]. Hum Pathol,1990,21(4):363–381.
|
[10] |
NCCN Clinical Practice Guidelines in Oncology: soft tissue sarcoma(2014)[EB/OL]. National Comprehensive Cancer Network,Inc.
URL
|
[11] |
Tanner EJ, Toussaint T, Leitao MM, et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth[J]. Gynecol Oncol, 2013, 129(1):140–144.
|
[12] |
Arend R, Bagaria M, Lewin SN, et al. Long term outcome and natural history of uterine adenosarcomas[J]. Gynecol Oncol,2010,119(2):305–308.
|
[13] |
Schroeder BA, Rodler ET, Loggers ET,et al.Clinical benefitof trabectedin in uterine adenosarcoma[J].Med Oncol, 2013,30(2):501–503.
|
[14] |
Stacchiotti S,Negri T,Zaffaroni N, et al.Sunitinib in advanced alveolar soft part sarcoma:evidence of a direct antitumor effect[J]. Ann Oncol, 2011,22(7):1682–1690.
|
[15] |
Carroll A,Ramirez PT,Westin SN,et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence[J]. Gynecol Oncol, 2014,135(3):455–461.
|
[16] |
Zhou M, Zhao G,Zhao F,et al. Alveolar soft part sarcoma: a clinicopathological analysis of 21 cases[J]. J Clin Exp Pathol, 2010, 26(1):63–66.
|